Feedback / Questions
BRL-201 - BRL Medicine
https://www.onclive.com/view/crispr-based-anti-cd19-car-t-cell-therapy-is-safe-and-effective-in-relapsed-refractory-nhl
Jan 9, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next